{"id":"c94b1c3b-0904-54a9-8615-08d5eb83cb14","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-it-still-makes-prostaglandins","predicate":"produces","statement":"Acetylated cyclooxygenase-2 also retains cyclooxygenase activity forming predominantly 15R-configuration prostaglandins, 70% or 62% 15R by radiolabelled substrate or LC-MS respectively, and although the Km of arachidonic acid for the acetylated enzyme was about threefold lower than for uninhibited enzyme the catalytic efficiency for prostaglandin formation was reduced tenfold through a decrease in Vmax.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"17b33d4c-bd36-5b7d-9de7-0df9c952108b","mechanism_event_label":"The rerouted enzyme has not stopped making prostaglandins; it makes mirror-image ones, more slowly.","subject":{"id":"cda05399-1c07-5459-b8e2-0edcf5066e94","slug":"acetylated-cox2","display_name":"Aspirin-acetylated cyclooxygenase-2","entity_type_key":"protein_state"},"object":{"id":"0f8ee79e-fa8b-5e30-ab80-6bd1843ae27b","slug":"15r-prostaglandins","display_name":"15R-configuration prostaglandins","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"17b33d4c-bd36-5b7d-9de7-0df9c952108b","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-it-still-makes-prostaglandins-event","event_type":"biochemical_relationship","label":"The rerouted enzyme has not stopped making prostaglandins; it makes mirror-image ones, more slowly.","description":"Acetylated cyclooxygenase-2 also retains cyclooxygenase activity forming predominantly 15R-configuration prostaglandins, 70% or 62% 15R by radiolabelled substrate or LC-MS respectively, and although the Km of arachidonic acid for the acetylated enzyme was about threefold lower than for uninhibited enzyme the catalytic efficiency for prostaglandin formation was reduced tenfold through a decrease in Vmax.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"8064b388-cb0d-543c-8932-9f8042d44193","slug":"prostaglandin-h2","display_name":"Prostaglandin H2","entity_type_key":"small_molecule"},"role":"native_product","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"39f9446f-52a6-502d-b507-91137726f82c","slug":"arachidonic-acid","display_name":"AA","entity_type_key":"small_molecule"},"role":"substrate","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"cda05399-1c07-5459-b8e2-0edcf5066e94","slug":"acetylated-cox2","display_name":"Aspirin-acetylated cyclooxygenase-2","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"0f8ee79e-fa8b-5e30-ab80-6bd1843ae27b","slug":"15r-prostaglandins","display_name":"15R-configuration prostaglandins","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/aspirin-research/30096040.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\", \"start_char\": 0, \"end_char\": 1666, \"text_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Aspirin acetylation, with lipopolysaccharide-induced cyclooxygenase-2 in leukocytes and a thromboxane receptor agonist on platelets","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Shows the acetylated enzyme keeps more of its original chemistry than the HETE story implies, and links the product to a measured platelet effect. Isolated cells rather than treated people.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The rerouted enzyme has not stopped making prostaglandins; it makes mirror-image ones, more slowly.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Recombinant enzyme and isolated leukocytes and platelets","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"bdd09332-eadb-50cf-bcbe-1aad4d5dfd31","evidence_kind":"source_excerpt","locator":"Lines 286-297","start_line":286,"end_line":297,"excerpt":"### asa-it-still-makes-prostaglandins\nAcetylated cyclooxygenase-2 also retains cyclooxygenase activity forming predominantly 15R-configuration prostaglandins, 70% or 62% 15R by radiolabelled substrate or LC-MS respectively, and although the Km of arachidonic acid for the acetylated enzyme was about threefold lower than for uninhibited enzyme the catalytic efficiency for prostaglandin formation was reduced tenfold through a decrease in Vmax.\nCondition category: normal\nnutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.\nplain_language: The rerouted enzyme has not stopped making prostaglandins; it makes mirror-image ones, more slowly.\norganism: Human\ntissue_or_cell_type: Recombinant enzyme and isolated leukocytes and platelets\nexperimental_model: Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays\nlimitations: Shows the acetylated enzyme keeps more of its original chemistry than the HETE story implies, and links the product to a measured platelet effect. Isolated cells rather than treated people.\nexposure: Aspirin acetylation, with lipopolysaccharide-induced cyclooxygenase-2 in leukocytes and a thromboxane receptor agonist on platelets\nevidence_span: {\"source_cache\": \"artifacts/aspirin-research/30096040.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\", \"start_char\": 0, \"end_char\": 1666, \"text_sha256\": \"2bd9c817ec4fe31752028634955f604eb00829efc93a72d5fc7e22be7f5739b8\"}\n[asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","model_system":"Radiolabelled substrate and LC-MS analysis of aspirin-acetylated COX-2 products, with human leukocytes and platelet aggregation assays","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [asa-p30096040] Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation. (2019). https://pubmed.ncbi.nlm.nih.gov/30096040/ DOI: 10.1096/fj.201801018r","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"712cf519-cd27-5a8b-9e2f-961a98d7a27e","stable_key":"import-f8641d02-8413-5bd8-92e9-62ad49286e81","title":"Aspirin: the serine it acetylates, the enzyme that acetylation creates, the dose that separates platelet from vessel wall, and the metabolite that is a different drug (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"93dd4343051c131e40d4fc3c95a978cd65478c13dcdb3f2d42507c49b09cb647","revision_id":"694e8ee7-49ca-5e6c-b58b-8ba8f82c2ad8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}